2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

Gallwitz, Baptist; Rosenstock, Julio; Rauch, T.; Bhattacharya, Subir; Patel, Sanjay; Eynatten, Maximilian von; Dugi, Klaus A.; Woerle, Hans-Juergen

doi:10.1016/s0140-6736(12)60691-6

Cited by 314 publications

(295 citation statements)

References 29 publications

Supporting

Mentioning

272

Contrasting

Unclassified

Order By: Relevance

“…Both groups of anti-diabetic agents (GLP-1 RA, DPP-4 inhibitors) are very promising therapy in type 2 overweight or obese diabetic patients [17][18][19].…”

Section: Pharmacotherapy Type 2 Obese Diabetic Patientsmentioning

confidence: 99%

Weight Loss Pharmacotherapy of Obese Non-Diabetic and Type 2 Diabetic Patients

Ä1⁄2ubomíra¹

2015

J Obes Weight Loss Ther

View full text Add to dashboard Cite

The first line in the treatment of obesity is a combination of a low calorie diet, increased physical activity and behavioural therapy. Unless these options fail, should be considered an effective and safe pharmacotherapy. The market situation in anti-obesity treatment will change in a relatively short time; the combination anti-obesity therapy is entering into clinical practice. Currently in Europe we have three drugs approved for long-term chronic treatment of obesity. In addition to the orlistat EMA approved a combination of naltrexon SR/bupropion SR and liraglutide 3.0 mg. A specific feature management of obese diabetic patients is the selection of weight neutral or weight-reducing anti-diabetic treatment (oral anti-diabetics, insulin), but also weight neutral treatment associated with co-morbidities.

show abstract

“…Both groups of anti-diabetic agents (GLP-1 RA, DPP-4 inhibitors) are very promising therapy in type 2 overweight or obese diabetic patients [17][18][19].…”

Section: Pharmacotherapy Type 2 Obese Diabetic Patientsmentioning

confidence: 99%

Weight Loss Pharmacotherapy of Obese Non-Diabetic and Type 2 Diabetic Patients

Ä1⁄2ubomíra¹

2015

J Obes Weight Loss Ther

View full text Add to dashboard Cite

show abstract

“…In the Liraglutide Effect and Action in Diabetes 2 (LEAD 2) trial, 4 mg of glimepiride daily was as effective as liraglutide 1.2 or 1.8 mg daily in lowering HbA 1c in subjects taking metformin (18). Glimepiride also has been shown to be as effective as the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin when added to metformin in patients suboptimally controlled on metformin alone (19). Longer-term studies would, of course, be welcomed to determine whether or not newer drugs are as safe and effective as SUs.…”

Section: Dwilliam T Cefalu Editor In Chief Diabetes Carementioning

confidence: 99%

Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? Yes, They Continue to Serve Us Well!

Abrahamson

2014

Diabetes Care

View full text Add to dashboard Cite

Since their introduction to clinical practice in the 1950s, sulfonylureas have been widely prescribed for use in patients with type 2 diabetes. Of all the other medications currently available for clinical use, only metformin has been used more frequently. However, several new drug classes have emerged that are reported to have equal glucose-lowering efficacy and greater safety when added to treatment of patients in whom metformin monotherapy is no longer sufficient. Moreover, current arguments also suggest that the alternative drugs may be superior to sulfonylureas with regard to the risk of cardiovascular complications. Thus, while there is universal agreement that metformin should remain the first-line pharmacologic therapy for those in whom lifestyle modification is insufficient to control hyperglycemia, there is no consensus as to which drug should be added to metformin. Therefore, given the current controversy, we provide a Point-Counterpoint on this issue. In the point narrative presented below, Dr. Abrahamson provides his argument suggesting that avoiding use of sulfonylureas as a class of medication as an add-on to metformin is not appropriate as there are many patients whose glycemic control would improve with use of these drugs with minimal risk of adverse events. In the following counterpoint narrative, Dr. Genuth suggests there is no longer a need for sulfonylureas to remain a first-line addition to metformin for those patients whose clinical characteristics are appropriate and whose health insurance and/or financial resources make an alternative drug affordable. —William T. Cefalu Editor in Chief, Diabetes Care

show abstract

“…In a 2-year double-blind trial, T2DM patients on stable metformin alone or with one additional oral antidiabetic drug (washed out during screening) were randomly assigned to linagliptin (5 mg; n=777) or glimepiride (1-4 mg; n=775) orally once daily in addition to metformin (daily dose ≥ 1500 mg in 93% of patients) 65 . Reductions in adjusted mean HbA1c from baseline (7.69% in both groups) to week 104 were similar in the linagliptin (-0.16%) and glimepiride groups (-0.36%; difference 0.20%, 97.5% CI 0.09-0.30), meeting the predefined non-inferiority criterion of 0.35%.…”

Section: Comparison Versus a Sulfonylureamentioning

confidence: 99%

Efficacy and safety of Jentadueto® (linagliptin plus metformin)

Scheen¹

2013

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

Cited by 314 publications

References 29 publications

Weight Loss Pharmacotherapy of Obese Non-Diabetic and Type 2 Diabetic Patients

Weight Loss Pharmacotherapy of Obese Non-Diabetic and Type 2 Diabetic Patients

Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? Yes, They Continue to Serve Us Well!

Efficacy and safety of Jentadueto® (linagliptin plus metformin)

Contact Info

Product

Resources

About